Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587673 · ClinicalTrials.gov registry record · Phase 1
High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05587673: Completed Phase 1 study, sponsored by Stanford University.
NCT05587673 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05587673, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will examine whether delivery of high dose steroids, directly into the inflamed bowel via its arterial blood supply, will be better for treating uncontrolled flares of inflammatory bowel disease in patients compared to conventional intra-venous or oral administration of this drug. Patients aged 4-25 years of age will be recruited. In this study, the Investigator hopes to also learn how this directed steroid delivery during an active flare will improve patient symptoms as well as the appearance of inflamed segments of bowel determined by imaging or biopsy (i.e. at the time of endoscopy). Additional data will determine how the blood vessels in the bowel affect, and potentially even drive the mechanisms, of inflammatory bowel disease.
Interventions
- DRUG Methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2024-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05587673
The ClinicalTrials.gov registry entry for NCT05587673 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylprednisolone is the first listed.
NCT05587673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05587673 about?
NCT05587673 is a clinical study titled "High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)". This study will examine whether delivery of high dose steroids, directly into the inflamed bowel via its arterial blood supply, will be better for treating uncontrolled flares of inflammatory bowel disease in patients compared to conventional intra-venous or oral administration of this drug. Patient...
What is the current status of trial NCT05587673?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2022-10-06. Estimated completion is 2024-10-11.
What interventions are being tested in trial NCT05587673?
The interventions under investigation include: Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT05587673?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.